Eltrombopag monotherapy can improve hematopoiesis in patients with low to intermediate risk-1 myelodysplastic syndrome

Myelodysplastic syndromes (MDS) are a group of clonal myeloid disorders characterized by low blood counts and a propensity to develop acute myeloid leukemia. The management of lowerrisk (LR) MDS with persistent cytopenias remains suboptimal. Eltrombopag, a thrombopoietin-receptor agonist, can improv...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Haematologica
Main Authors: Vicente, Alana, Patel, Bhavisha A., Gutierrez-Rodrigues, Fernanda, Groarke, Emma M., Giudice, Valentina, Lotter, Jennifer, Feng, Xingmin, Kajigaya, Sachiko, Weinstein, Barbara, Barranta, Evette, Olnes, Matthew J., Parikh, Ankur R., Albitar, Maher, Wu, Colin O., Shalhoub, Ruba, Calvo, Katherine R., Townsley, Danielle M., Scheinberg, Phillip, Dunbar, Cynthia E., Young, Neal S., Winkler, Thomas
Formato: Artigo
Idioma:Inglês
Publicado em: Fondazione Ferrata Storti 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7716353/
https://ncbi.nlm.nih.gov/pubmed/33256377
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2020.249995
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados